|
1.Dalessio, D.J., Current concepts. Seizure disorders and pregnancy. N Engl J Med, 1985. 312(9): p. 559-63. 2.Davis, L.L., et al., Comprehensive review of the psychiatric uses of valproate. J Clin Psychopharmacol, 2000. 20(1 Suppl 1): p. 1S-17S. 3.Diane, C.L., Valproic acid: how it works. Or not. Clinical Neuroscience Research, 2004. 4: p. 215-225. 4.Zaccara, G., A. Messori, and F. Moroni, Clinical pharmacokinetics of valproic acid--1988. Clin Pharmacokinet, 1988. 15(6): p. 367-89. 5.Klotz, U. and K.H. Antonin, Pharmacokinetics and bioavailability of sodium valproate. Clin Pharmacol Ther, 1977. 21(6): p. 736-43. 6.Deckers, C.L., et al., Selection of antiepileptic drug polytherapy based on mechanisms of action: the evidence reviewed. Epilepsia, 2000. 41(11): p. 1364-74. 7.Wassef, A.A., et al., Critical review of GABA-ergic drugs in the treatment of schizophrenia. J Clin Psychopharmacol, 1999. 19(3): p. 222-32. 8.Perry, P.J., et al., Correlation of valproate plasma concentrations and dose in bipolar affective disorder. J Clin Psychopharmacol, 2000. 20(2): p. 277-9. 9.Bowden, C.L., et al., Relation of serum valproate concentration to response in mania. Am J Psychiatry, 1996. 153(6): p. 765-70. 10.Winter's, M.E., Basic clinical pharmacokinetics. 3rd ed. 1994: vancover:applied therapeutics. 11.Felix, S., et al., Dose-related pharmacokinetics and pharmacodynamics of valproate in the elderly. J Clin Psychopharmacol, 2003. 23(5): p. 471-8. 12.ES, E.L.D., et al., Pharmacokinetic modelling of valproic acid from routine clinical data in Egyptian epileptic patients. Eur J Clin Pharmacol, 2004. 59(11): p. 783-90. 13.Park, H.M., et al., Population pharmacokinetics of intravenous valproic acid in Korean patients. J Clin Pharm Ther, 2002. 27(6): p. 419-25. 14.Yukawa, E., et al., Population-based investigation of valproic acid relative clearance using nonlinear mixed effects modeling: influence of drug-drug interaction and patient characteristics. J Clin Pharmacol, 1997. 37(12): p. 1160-7. 15.Yukawa, E., Population-based investigations of drug relative clearance using nonlinear mixed-effect modelling from information generated during the routine clinical care of patients. J Clin Pharm Ther, 1999. 24(2): p. 103-13. 16.FDA., Guidance for Industry - population pharmacokinetics. 1999. 17.Whiting, B., A.W. Kelman, and J. Grevel, Population pharmacokinetics. Theory and clinical application. Clin Pharmacokinet, 1986. 11(5): p. 387-401. 18.Beal, S.L. and L.B. Sheiner, NONMEM User Guides. 1989-98: GloboMax LLC,Hanover,MD. 19.Tam, V.H., S.L. Preston, and G.L. Drusano, Optimal sampling schedule design for populations of patients. Antimicrob Agents Chemother, 2003. 47(9): p. 2888-91. 20.Ette, E.I., et al., Analysis of animal pharmacokinetic data: performance of the one point per animal design. J Pharmacokinet Biopharm, 1995. 23(6): p. 551-66. 21.Jonsson, E.N., J.R. Wade, and M.O. Karlsson, Comparison of some practical sampling strategies for population pharmacokinetic studies. J Pharmacokinet Biopharm, 1996. 24(2): p. 245-63. 22.Suematsu, F., et al., Population analysis for the optimization of digoxin treatment in Japanese paediatric patients. J Clin Pharm Ther, 1999. 24(3): p. 203-8. 23.Breant, V., et al., How many patients and blood levels are necessary for population pharmacokinetic analysis? A study of a one compartment model applied to cyclosporine. Eur J Clin Pharmacol, 1996. 51(3-4): p. 283-8. 24.Fukuda, T., et al., Population pharmacokinetics of theophylline in very premature Japanese infants with apnoea. J Clin Pharm Ther, 2005. 30(6): p. 591-6. 25.Jiao, Z., et al., Population pharmacokinetics of carbamazepine in Chinese epilepsy patients. Ther Drug Monit, 2003. 25(3): p. 279-86. 26.Jiao, Z., et al., Population pharmacokinetic modeling of steady state clearance of carbamazepine and its epoxide metabolite from sparse routine clinical data. J Clin Pharm Ther, 2004. 29(3): p. 247-56. 27.Yukawa, E., et al., Epidemiologic investigation of the relative clearance of haloperidol by mixed-effect modeling using routine clinical pharmacokinetic data in Japanese patients. J Clin Psychopharmacol, 2000. 20(6): p. 685-90. 28.Dutta, S., et al., Divalproex-ER pharmacokinetics in older children and adolescents. Pediatr Neurol, 2004. 30(5): p. 330-7. 29.Sheiner, L.B. and S.L. Beal, Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm, 1981. 9(4): p. 503-12. 30.Ette, E.I., et al., Model appropriateness and population pharmacokinetic modeling. J Clin Pharmacol, 2003. 43(6): p. 610-23. 31.Chen, L.C., et al., Lack of pharmacokinetic interaction between valproic acid and a traditional Chinese medicine, Paeoniae Radix, in healthy volunteers. J Clin Pharm Ther, 2000. 25(6): p. 453-9. 32.Poolsup, N., A. Li Wan Po, and T.L. Knight, Pharmacogenetics and psychopharmacotherapy. J Clin Pharm Ther, 2000. 25(3): p. 197-220. 33.Yukawa, E., A feasibility study of the multiple-peak approach for pharmacokinetic screening: population-based investigation of valproic acid relative clearance using routine clinical pharmacokinetic data. J Pharm Pharmacol, 1995. 47(12A): p. 1048-52. 34.Kodama, Y., et al., Gender- or age-related binding characteristics of valproic acid to serum proteins in adult patients with epilepsy. Eur J Pharm Biopharm, 2001. 52(1): p. 57-63. 35.Botha, J.H., A.L. Gray, and R. Miller, A model for estimating individualized valproate clearance values in children. J Clin Pharmacol, 1995. 35(10): p. 1020-4. 36.Yukawa, E., et al., Pharmacoepidemiologic investigation of a clonazepam-valproic acid interaction by mixed effect modeling using routine clinical pharmacokinetic data in Japanese patients. J Clin Pharm Ther, 2003. 28(6): p. 497-504. 37.Blanco-Serrano, B., et al., Population estimation of valproic acid clearance in adult patients using routine clinical pharmacokinetic data. Biopharm Drug Dispos, 1999. 20(5): p. 233-40. 38.Yukawa, E., et al., Population pharmacokinetic investigation of disopyramide by mixed effect modelling using routine clinical pharmacokinetic data in Japanese patients. J Clin Pharm Ther, 2005. 30(4): p. 401-5. 39.Yukawa, E., et al., Population pharmacokinetic investigation of phenobarbital by mixed effect modelling using routine clinical pharmacokinetic data in Japanese neonates and infants. J Clin Pharm Ther, 2005. 30(2): p. 159-63. 40.Reith, D.M., et al., Population pharmacokinetic modeling of steady state carbamazepine clearance in children, adolescents, and adults. J Pharmacokinet Pharmacodyn, 2001. 28(1): p. 79-92. 41.Muller-Oerlinghausen, B., et al., Valproate as an adjunct to neuroleptic medication for the treatment of acute episodes of mania: a prospective, randomized, double-blind, placebo-controlled, multicenter study. European Valproate Mania Study Group. J Clin Psychopharmacol, 2000. 20(2): p. 195-203. 42.Serrano, B.B., et al., Valproate population pharmacokinetics in children. J Clin Pharm Ther, 1999. 24(1): p. 73-80. 43.Micromedex® Healthcare Series, Thomson Micromedex, Greenwood Village, Colorado(2006).
|